Hadassah

COVID-19 Plasma Therapy Shows Promise in Hadassah Clinical Trial

Friday, Sep 11 2020

At Hadassah Hospital Ein Kerem, symptoms improved in 11 of the 12 COVID-19 patients who were given a plasma-derived therapy developed by Kamada, an Israeli biopharmaceutical company. On average, the patients were able to go home in less than five days.

The patients, all of whom had pneumonia but were not on ventilators, were participants in a phase 1/2 clinical trial at Hadassah. They were treated with Kamada’s “passive vaccine,” comprised of a hyperimmune immunoglobulin product that provides the patient with antibodies to fight the disease.

The antibodies were harvested from recovered COVID-19 patients who volunteered to donate their plasma. The plasma donations, collected by Hadassah’s Blood Bank, were transferred to Kamada’s facilities together with doses collected by Magen David Adom.

The first patient to be given the plasma-derived therapy was treated at Hadassah in June. Two other patients were also successfully treated before the clinical trial was launched.

Five of the patients have been followed up for 21 days, two for 14 days, and the additional five patients for seven days. Plans are to monitor these patients for a total of 84 days.

In an interview with The Jerusalem Post, Kamada’s chief executive officer Amir London said that he believes his company is the first one globally to complete manufacturing of a plasma-derived IgG product for the treatment of COVID-19. A “plasma-derived IgG product, as developed by Kamada,” he reported, “is considered to have multiple advantages over convalescent plasma transfusion, including standardized antibody levels, higher potency, extensive viral inactivation processing, the absence of a blood-type matching requirement, smaller infusion volumes, the ability to be produced in large quantities, an expected longer shelf life, and preferred storage conditions.”

Read the full story in The Jerusalem Post.

Related Stories

alt_text

Wednesday, Sep 16 2020

Hadassah to Conduct Clinical Trial of Israeli-Made COVID-19 Vaccine

The Hadassah Medical Organization is slated to begin a clinical trial with an Israeli-made COVID-19 vaccine in October. One hundred volunteers are being recruited to participate at Hadassah and Tel Aviv’s Sheba Medical Center.

READ MORE ›
alt_text

Tuesday, Sep 15 2020

Where Others Gave Up: Hadassah Liver Specialists Save a Father’s Life

Many doctors predicted that Amir Hazan, a 46-year-old father of two, would live for only two years. First diagnosed in 2011 with cirrhosis of the liver, he experienced a rapid decline in his health about a year ago.

READ MORE ›
alt_text

Tuesday, Sep 15 2020

Hadassah Forging Ties With Medical Professionals As UAE, Bahrain Recognize Israel

Hadassah, The Women’s Zionist Organization of America, Inc. National President Rhoda Smolow released the following statement today following the signing of the Abraham Accords...

READ MORE ›
alt_text

Monday, Sep 14 2020

Judean Palm Dates Make a Comeback After 2000 Years, Thanks to HMO Doctor’s Quest

As a pediatric gastroenterologist and Director of the Louis L. Borick Natural Medicine Research Center at the Hadassah Hospital Ein Kerem in Jerusalem, Dr. Sarah Sallon has long been interested in natural remedies.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More